Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iNTS-TCV
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**iNTS-TCV** is an investigational vaccine under clinical development for the prevention of invasive non-typhoidal Salmonella (iNTS) disease and typhoid fever. The vaccine is a combination product: it contains Generalized Modules for Membrane Antigens (GMMA) derived from outer membrane vesicles of Salmonella Enteritidis and Salmonella Typhimurium, the two most common causes of invasive NTS disease, adsorbed onto Alhydrogel, and is combined with a Typhoid Conjugate Vaccine (TCV) component. The parent bacteria are genetically modified to enhance GMMA production and reduce endotoxin toxicity by targeting the tolR, msbB, and pagP genes. iNTS-TCV is designed to induce immunity against the O-antigens of these Salmonella serovars and Vi polysaccharide of Salmonella Typhi, inducing antibody and cell-mediated immune responses. Clinical studies are underway to evaluate safety, tolerability, and immunogenicity in healthy adults in Europe and Africa[1][2][3].
- Brand names
- iNTS-TCV
- Other names
- iNTS-TCV
02
Targets
O9 (Salmonella Enteritidis O-antigen polysaccharide)Salmonella Typhimurium O:4 O-antigen polysaccharideVi antigen (Vi capsular polysaccharide)
Beyond the preview
Go deeper on iNTS-TCV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iNTS-TCV.